Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero soars as drug shows it reverses scarring in liver disease patients
Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
STAT1d
Akero drug reverses liver scarring in study of severe MASH patients
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
STAT1d
Bariatric surgery halted progression of liver disease in patients with obesity and cirrhosis, study finds
Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...